左旋咪唑治疗频繁复发肾病综合征的短期疗效:一项单中心前瞻性队列研究

Frontiers in nephrology Pub Date : 2025-03-21 eCollection Date: 2025-01-01 DOI:10.3389/fneph.2025.1539776
Sabeeta Khatri, Irshad Ali Bajeer, Aasia Zubair, Ali Asghar Anwar Lanewala, Seema Hashmi
{"title":"左旋咪唑治疗频繁复发肾病综合征的短期疗效:一项单中心前瞻性队列研究","authors":"Sabeeta Khatri, Irshad Ali Bajeer, Aasia Zubair, Ali Asghar Anwar Lanewala, Seema Hashmi","doi":"10.3389/fneph.2025.1539776","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to describe the outcome of levamisole (LEVA) treatment in children with frequently relapsing nephrotic syndrome (FRNS).</p><p><strong>Methods: </strong>This prospective cohort study was conducted at the Department of Pediatric Nephrology, Sindh Institute of Urology and Transplantation from 1 January 2019 to 31 December 2020. Children aged 1-18 years diagnosed with FRNS were included. LEVA was started with a dose of 2-2.5 mg/kg every other day for 2 years along with low-dose prednisolone in the first year.</p><p><strong>Results: </strong>A total of 70 children with FRNS were enrolled in the study. The median age was 7.5 [interquartile range (IQR) 5.0-9.6 years] with a slight predominance of boys (42, 60%). The mean number of relapses and cumulative dose of steroids significantly decreased after 2 years of LEVA therapy and during the 1-year follow-up. LEVA non-response was observed in half of the studied participants (28, 46%). The responders and non-responders were comparable in terms of cumulative dose of steroids and number of relapses in the year prior to starting LEVA [5,242 ± 1,738 versus 4,910 ± 1,469 (p-value = 0.52) and 5.4 ± 2.4 versus 5.2 ± 2.1 (p-value = 0.85)].</p><p><strong>Conclusion: </strong>LEVA therapy resulted in a substantial reduction in the frequency of relapses and cumulative dosage, indicating its potential as an alternative option for children with relapsing disease.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"5 ","pages":"1539776"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11969797/pdf/","citationCount":"0","resultStr":"{\"title\":\"Short-term outcome of levamisole in frequently relapsing nephrotic syndrome: a single-center prospective cohort study.\",\"authors\":\"Sabeeta Khatri, Irshad Ali Bajeer, Aasia Zubair, Ali Asghar Anwar Lanewala, Seema Hashmi\",\"doi\":\"10.3389/fneph.2025.1539776\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>This study aims to describe the outcome of levamisole (LEVA) treatment in children with frequently relapsing nephrotic syndrome (FRNS).</p><p><strong>Methods: </strong>This prospective cohort study was conducted at the Department of Pediatric Nephrology, Sindh Institute of Urology and Transplantation from 1 January 2019 to 31 December 2020. Children aged 1-18 years diagnosed with FRNS were included. LEVA was started with a dose of 2-2.5 mg/kg every other day for 2 years along with low-dose prednisolone in the first year.</p><p><strong>Results: </strong>A total of 70 children with FRNS were enrolled in the study. The median age was 7.5 [interquartile range (IQR) 5.0-9.6 years] with a slight predominance of boys (42, 60%). The mean number of relapses and cumulative dose of steroids significantly decreased after 2 years of LEVA therapy and during the 1-year follow-up. LEVA non-response was observed in half of the studied participants (28, 46%). The responders and non-responders were comparable in terms of cumulative dose of steroids and number of relapses in the year prior to starting LEVA [5,242 ± 1,738 versus 4,910 ± 1,469 (p-value = 0.52) and 5.4 ± 2.4 versus 5.2 ± 2.1 (p-value = 0.85)].</p><p><strong>Conclusion: </strong>LEVA therapy resulted in a substantial reduction in the frequency of relapses and cumulative dosage, indicating its potential as an alternative option for children with relapsing disease.</p>\",\"PeriodicalId\":73091,\"journal\":{\"name\":\"Frontiers in nephrology\",\"volume\":\"5 \",\"pages\":\"1539776\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11969797/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in nephrology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3389/fneph.2025.1539776\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in nephrology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fneph.2025.1539776","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

简介:本研究旨在描述左旋咪唑(LEVA)治疗儿童频繁复发肾病综合征(FRNS)的结果。方法:这项前瞻性队列研究于2019年1月1日至2020年12月31日在信德省泌尿外科和移植研究所儿科肾病科进行。被诊断为FRNS的1-18岁儿童被纳入研究。LEVA开始时的剂量为每隔一天2-2.5 mg/kg,持续2年,第一年使用低剂量强的松龙。结果:共有70名FRNS患儿入组研究。中位年龄为7.5岁[四分位间距(IQR) 5.0-9.6岁],男孩略占优势(42.60%)。经过2年的LEVA治疗和1年的随访,平均复发次数和类固醇累积剂量显著降低。在一半的研究参与者(28.46%)中观察到LEVA无反应。应答者和无应答者在开始LEVA前一年的类固醇累积剂量和复发次数方面具有可比性[5,242±1,738对4,910±1,469 (p值= 0.52)和5.4±2.4对5.2±2.1 (p值= 0.85)]。结论:LEVA治疗导致复发频率和累积剂量的显著降低,表明其作为复发性疾病儿童的替代选择的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Short-term outcome of levamisole in frequently relapsing nephrotic syndrome: a single-center prospective cohort study.

Introduction: This study aims to describe the outcome of levamisole (LEVA) treatment in children with frequently relapsing nephrotic syndrome (FRNS).

Methods: This prospective cohort study was conducted at the Department of Pediatric Nephrology, Sindh Institute of Urology and Transplantation from 1 January 2019 to 31 December 2020. Children aged 1-18 years diagnosed with FRNS were included. LEVA was started with a dose of 2-2.5 mg/kg every other day for 2 years along with low-dose prednisolone in the first year.

Results: A total of 70 children with FRNS were enrolled in the study. The median age was 7.5 [interquartile range (IQR) 5.0-9.6 years] with a slight predominance of boys (42, 60%). The mean number of relapses and cumulative dose of steroids significantly decreased after 2 years of LEVA therapy and during the 1-year follow-up. LEVA non-response was observed in half of the studied participants (28, 46%). The responders and non-responders were comparable in terms of cumulative dose of steroids and number of relapses in the year prior to starting LEVA [5,242 ± 1,738 versus 4,910 ± 1,469 (p-value = 0.52) and 5.4 ± 2.4 versus 5.2 ± 2.1 (p-value = 0.85)].

Conclusion: LEVA therapy resulted in a substantial reduction in the frequency of relapses and cumulative dosage, indicating its potential as an alternative option for children with relapsing disease.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信